<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Bolt Metals Corp — News on 6ix</title>
<link>https://6ix.com/company/bolt-metals-corp</link>
<description>Latest news and press releases for Bolt Metals Corp on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Thu, 12 Mar 2026 20:05:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/bolt-metals-corp" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo683682be78dffbe2df169039.webp</url>
<title>Bolt Metals Corp</title>
<link>https://6ix.com/company/bolt-metals-corp</link>
</image>
<item>
<title>Bolt Biotherapeutics Reports Fourth Quarter and Full-Year 2025 Financial Results and Provides Business Update</title>
<link>https://6ix.com/company/bolt-metals-corp/news/bolt-biotherapeutics-reports-fourth-quarter-and-full-year-2025-financial-results-and-provides-business-update-5</link>
<guid isPermaLink="true">https://6ix.com/company/bolt-metals-corp/news/bolt-biotherapeutics-reports-fourth-quarter-and-full-year-2025-financial-results-and-provides-business-update-5</guid>
<pubDate>Thu, 12 Mar 2026 20:05:00 GMT</pubDate>
<description>First-in-class immune-stimulating antibody conjugate BDC-4182 in Phase 1 dose escalation study, i...</description>
</item>
<item>
<title>Bolt Metals Announces Upsize Non-Brokered Private Placement to $6,000,000</title>
<link>https://6ix.com/company/bolt-metals-corp/news/bolt-metals-announces-upsize-non-200000909</link>
<guid isPermaLink="true">https://6ix.com/company/bolt-metals-corp/news/bolt-metals-announces-upsize-non-200000909</guid>
<pubDate>Fri, 09 Jan 2026 20:00:00 GMT</pubDate>
<description>VANCOUVER, BC / ACCESS Newswire / January 9, 2026 /Bolt Metals Corp. ("Bolt" or the "Company") (TSXV:BOLT)(OTC:PCRCF)(FSE:A3D8AK), a North American mineral acquisition and exploration company, is pleased to announce that further to the Company's news ...</description>
</item>
<item>
<title>Bolt Biotherapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update</title>
<link>https://6ix.com/company/bolt-metals-corp/news/bolt-biotherapeutics-reports-third-quarter-2025-financial-results-and-provides-business-update</link>
<guid isPermaLink="true">https://6ix.com/company/bolt-metals-corp/news/bolt-biotherapeutics-reports-third-quarter-2025-financial-results-and-provides-business-update</guid>
<pubDate>Wed, 12 Nov 2025 21:05:00 GMT</pubDate>
<description>Initial clinical data for BDC-4182 Phase 1 dose escalation study expected in 3Q 2026 Cash...</description>
</item>
<item>
<title>Bolt Biotherapeutics Provides Update on BDC-4182 and Extends Cash Runway into 2027</title>
<link>https://6ix.com/company/bolt-metals-corp/news/bolt-biotherapeutics-provides-update-on-bdc-4182-and-extends-cash-runway-into-2027</link>
<guid isPermaLink="true">https://6ix.com/company/bolt-metals-corp/news/bolt-biotherapeutics-provides-update-on-bdc-4182-and-extends-cash-runway-into-2027</guid>
<pubDate>Wed, 01 Oct 2025 20:05:00 GMT</pubDate>
<description>Initial clinical data for BDC-4182 Phase 1 dose escalation study now expected in 3Q 2026 Comp...</description>
</item>
<item>
<title>Bolt Biotherapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update</title>
<link>https://6ix.com/company/bolt-metals-corp/news/bolt-biotherapeutics-reports-second-quarter-2025-financial-results-and-provides-business-update</link>
<guid isPermaLink="true">https://6ix.com/company/bolt-metals-corp/news/bolt-biotherapeutics-reports-second-quarter-2025-financial-results-and-provides-business-update</guid>
<pubDate>Thu, 14 Aug 2025 20:05:00 GMT</pubDate>
<description>Next-generation claudin 18.2 ISAC BDC-4182 now in Phase 1 dose-escalation study Cash bala...</description>
</item>
<item>
<title>Bolt Biotherapeutics Reports First Quarter 2025 Financial Results and Provides Business Update</title>
<link>https://6ix.com/company/bolt-metals-corp/news/bolt-biotherapeutics-reports-first-quarter-2025-financial-results-and-provides-business-update</link>
<guid isPermaLink="true">https://6ix.com/company/bolt-metals-corp/news/bolt-biotherapeutics-reports-first-quarter-2025-financial-results-and-provides-business-update</guid>
<pubDate>Mon, 12 May 2025 20:05:00 GMT</pubDate>
<description>BDC-4182 Phase 1 dose-escalation study now open for enrollment BDC-3042 Phase 1 dose-esca...</description>
</item>
<item>
<title>Bolt Biotherapeutics to Host KOL Conference Call and Webcast to Discuss BDC-3042 Phase 1 Results and Corporate Updates</title>
<link>https://6ix.com/company/bolt-metals-corp/news/bolt-biotherapeutics-to-host-kol-conference-call-and-webcast-to-discuss-bdc-3042-phase-1-results-and-corporate-updates</link>
<guid isPermaLink="true">https://6ix.com/company/bolt-metals-corp/news/bolt-biotherapeutics-to-host-kol-conference-call-and-webcast-to-discuss-bdc-3042-phase-1-results-and-corporate-updates</guid>
<pubDate>Thu, 08 May 2025 12:00:00 GMT</pubDate>
<description>Conference call and webcast on Monday, May 12, 2025, at 2:30 p.m. PT / 5:30 p.m. ET REDWOOD...</description>
</item>
<item>
<title>Bolt Biotherapeutics Presents Preclinical Results for Next-Generation Boltbody(TM) ISACs targeting CEA and PD-L1 at AACR Annual Meeting 2025</title>
<link>https://6ix.com/company/bolt-metals-corp/news/bolt-biotherapeutics-presents-preclinical-results-for-next-generation-boltbodytm-isacs-targeting-cea-and-pd-l1-at-aacr-annual-meeting-2025</link>
<guid isPermaLink="true">https://6ix.com/company/bolt-metals-corp/news/bolt-biotherapeutics-presents-preclinical-results-for-next-generation-boltbodytm-isacs-targeting-cea-and-pd-l1-at-aacr-annual-meeting-2025</guid>
<pubDate>Wed, 30 Apr 2025 20:05:00 GMT</pubDate>
<description>CEA-targeted ISAC elicits complete responses in mice and is well-tolerated in NHPs ...</description>
</item>
<item>
<title>Bolt Biotherapeutics Presents Results from the Phase 1 Dose-Escalation Clinical Study of BDC-3042 at AACR Annual Meeting 2025</title>
<link>https://6ix.com/company/bolt-metals-corp/news/bolt-biotherapeutics-presents-results-from-the-phase-1-dose-escalation-clinical-study-of-bdc-3042-at-aacr-annual-meeting-2025</link>
<guid isPermaLink="true">https://6ix.com/company/bolt-metals-corp/news/bolt-biotherapeutics-presents-results-from-the-phase-1-dose-escalation-clinical-study-of-bdc-3042-at-aacr-annual-meeting-2025</guid>
<pubDate>Fri, 25 Apr 2025 17:00:00 GMT</pubDate>
<description>BDC-3042 was well tolerated up to 10 mg/kg q2w with no dose-limiting toxicities and no drug-relat...</description>
</item>
<item>
<title>Bolt Biotherapeutics to Present Data from Phase 1 Dose-Escalation Clinical Study of BDC-3042 at AACR Annual Meeting 2025</title>
<link>https://6ix.com/company/bolt-metals-corp/news/bolt-biotherapeutics-to-present-data-from-phase-1-dose-escalation-clinical-study-of-bdc-3042-at-aacr-annual-meeting-2025</link>
<guid isPermaLink="true">https://6ix.com/company/bolt-metals-corp/news/bolt-biotherapeutics-to-present-data-from-phase-1-dose-escalation-clinical-study-of-bdc-3042-at-aacr-annual-meeting-2025</guid>
<pubDate>Tue, 25 Mar 2025 20:30:00 GMT</pubDate>
<description>REDWOOD CITY, Calif., March 25, 2025 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (Nasdaq: BOLT), a c...</description>
</item>
<item>
<title>Bolt Biotherapeutics Reports Fourth Quarter and Full-Year 2024 Financial Results and Provides Business Update</title>
<link>https://6ix.com/company/bolt-metals-corp/news/bolt-biotherapeutics-reports-fourth-quarter-and-full-year-2024-financial-results-and-provides-business-update</link>
<guid isPermaLink="true">https://6ix.com/company/bolt-metals-corp/news/bolt-biotherapeutics-reports-fourth-quarter-and-full-year-2024-financial-results-and-provides-business-update</guid>
<pubDate>Mon, 24 Mar 2025 20:20:00 GMT</pubDate>
<description>BDC-4182 on track to start a clinical trial in gastric cancer in second quarter 2025 BDC-3042...</description>
</item>
<item>
<title>Bolt Biotherapeutics to Participate in Upcoming March Conferences</title>
<link>https://6ix.com/company/bolt-metals-corp/news/bolt-biotherapeutics-to-participate-in-upcoming-march-conferences</link>
<guid isPermaLink="true">https://6ix.com/company/bolt-metals-corp/news/bolt-biotherapeutics-to-participate-in-upcoming-march-conferences</guid>
<pubDate>Tue, 25 Feb 2025 21:05:00 GMT</pubDate>
<description>REDWOOD CITY, Calif., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (Nasdaq: BOLT), a cl...</description>
</item>
<item>
<title>Bolt Biotherapeutics, Inc. Provides Update on Global Cancer Immunotherapy Co-Development with Toray Industries, Inc.</title>
<link>https://6ix.com/company/bolt-metals-corp/news/bolt-biotherapeutics-inc-provides-update-on-global-cancer-immunotherapy-co-development-with-toray-industries-inc</link>
<guid isPermaLink="true">https://6ix.com/company/bolt-metals-corp/news/bolt-biotherapeutics-inc-provides-update-on-global-cancer-immunotherapy-co-development-with-toray-industries-inc</guid>
<pubDate>Tue, 11 Feb 2025 21:05:00 GMT</pubDate>
<description>-- Targeting Unmet Needs for Treating Solid Tumors-- REDWOOD CITY, Calif., Feb. 11, 2025 (G...</description>
</item>
<item>
<title>Bolt Biotherapeutics, Inc. May Have Violated Securities Laws And Shareholders Are Urged To Participate In A Case With The Schall Law Firm</title>
<link>https://6ix.com/company/bolt-metals-corp/news/bolt-biotherapeutics-inc-may-have-violated-securities-laws-and-shareholders-are-urged-to-participate-in-a-case-with-the-schall-law-firm</link>
<guid isPermaLink="true">https://6ix.com/company/bolt-metals-corp/news/bolt-biotherapeutics-inc-may-have-violated-securities-laws-and-shareholders-are-urged-to-participate-in-a-case-with-the-schall-law-firm</guid>
<pubDate>Fri, 06 Sep 2024 15:00:00 GMT</pubDate>
<description>LOS ANGELES, CA / ACCESSWIRE / September 6, 2024 / The Schall Law Firm, a national shareholder r...</description>
</item>
<item>
<title>The Schall Law Firm Invites Investors To Contribute To A Securities Fraud Lawsuit Against Bolt Biotherapeutics Inc</title>
<link>https://6ix.com/company/bolt-metals-corp/news/the-schall-law-firm-invites-investors-to-contribute-to-a-securities-fraud-lawsuit-against-bolt-biotherapeutics-inc</link>
<guid isPermaLink="true">https://6ix.com/company/bolt-metals-corp/news/the-schall-law-firm-invites-investors-to-contribute-to-a-securities-fraud-lawsuit-against-bolt-biotherapeutics-inc</guid>
<pubDate>Thu, 05 Sep 2024 15:00:00 GMT</pubDate>
<description>LOS ANGELES, CA / ACCESSWIRE / September 5, 2024 / The Schall Law Firm, a national shareholder r...</description>
</item>
<item>
<title>Bolt Biotherapeutics Inc. May Have Violated Securities Regulations And Stakeholders Are Urged To Reach Out To The Schall Law Firm</title>
<link>https://6ix.com/company/bolt-metals-corp/news/bolt-biotherapeutics-inc-may-have-violated-securities-regulations-and-stakeholders-are-urged-to-reach-out-to-the-schall-law-firm</link>
<guid isPermaLink="true">https://6ix.com/company/bolt-metals-corp/news/bolt-biotherapeutics-inc-may-have-violated-securities-regulations-and-stakeholders-are-urged-to-reach-out-to-the-schall-law-firm</guid>
<pubDate>Wed, 04 Sep 2024 15:00:00 GMT</pubDate>
<description>LOS ANGELES, CA / ACCESSWIRE / September 4, 2024 / The Schall Law Firm, a national shareholder r...</description>
</item>
<item>
<title>BOLT DEADLINE TODAY: ROSEN, A LEADING LAW FIRM, Encourages Bolt Biotherapeutics, Inc. Investors to Secure Counsel Before Important September 3 Deadline in Securities Class Action - BOLT</title>
<link>https://6ix.com/company/bolt-metals-corp/news/bolt-deadline-today-rosen-a-leading-law-firm-encourages-bolt-biotherapeutics-inc-investors-to-secure-counsel-before-important-september-3-deadline-in-securities-class-action-bolt</link>
<guid isPermaLink="true">https://6ix.com/company/bolt-metals-corp/news/bolt-deadline-today-rosen-a-leading-law-firm-encourages-bolt-biotherapeutics-inc-investors-to-secure-counsel-before-important-september-3-deadline-in-securities-class-action-bolt</guid>
<pubDate>Tue, 03 Sep 2024 22:10:00 GMT</pubDate>
<description>New York, New York--(Newsfile Corp. - September 3, 2024) - WHY: Rosen Law Firm, a global invest...</description>
</item>
<item>
<title>FINAL BOLT DEADLINE: Bronstein, Gewirtz & Grossman LLC Reminds Bolt Biotherapeutics, Inc. Investors to Join the Class Action Lawsuit!</title>
<link>https://6ix.com/company/bolt-metals-corp/news/final-bolt-deadline-bronstein-gewirtz-and-grossman-llc-reminds-bolt-biotherapeutics-inc-investors-to-join-the-class-action-lawsuit</link>
<guid isPermaLink="true">https://6ix.com/company/bolt-metals-corp/news/final-bolt-deadline-bronstein-gewirtz-and-grossman-llc-reminds-bolt-biotherapeutics-inc-investors-to-join-the-class-action-lawsuit</guid>
<pubDate>Tue, 03 Sep 2024 18:00:00 GMT</pubDate>
<description>New York, New York--(Newsfile Corp. - September 3, 2024) - Bronstein, Gewirtz &amp; Grossman, LLC...</description>
</item>
<item>
<title>FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Bolt</title>
<link>https://6ix.com/company/bolt-metals-corp/news/final-deadline-alert-faruqi-and-faruqi-llp-investigates-claims-on-behalf-of-investors-of-bolt</link>
<guid isPermaLink="true">https://6ix.com/company/bolt-metals-corp/news/final-deadline-alert-faruqi-and-faruqi-llp-investigates-claims-on-behalf-of-investors-of-bolt</guid>
<pubDate>Tue, 03 Sep 2024 16:23:00 GMT</pubDate>
<description>Faruqi &amp; Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors W...</description>
</item>
<item>
<title>The Schall Law Firm Invites Investors In Bolt Biotherapeutics Inc To Participate In A Securities Fraud Lawsuit</title>
<link>https://6ix.com/company/bolt-metals-corp/news/the-schall-law-firm-invites-investors-in-bolt-biotherapeutics-inc-to-participate-in-a-securities-fraud-lawsuit</link>
<guid isPermaLink="true">https://6ix.com/company/bolt-metals-corp/news/the-schall-law-firm-invites-investors-in-bolt-biotherapeutics-inc-to-participate-in-a-securities-fraud-lawsuit</guid>
<pubDate>Tue, 03 Sep 2024 15:00:00 GMT</pubDate>
<description>LOS ANGELES, CA / ACCESSWIRE / September 3, 2024 / The Schall Law Firm, a national shareholder r...</description>
</item>
</channel>
</rss>